financetom
Business
financetom
/
Business
/
BloomZ Receives Nasdaq Extension to Regain Compliance; Shares Rise After Hours
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BloomZ Receives Nasdaq Extension to Regain Compliance; Shares Rise After Hours
Jun 6, 2025 1:35 PM

04:29 PM EDT, 06/06/2025 (MT Newswires) -- BloomZ ( BLMZ ) said Friday it received a letter from Nasdaq granting the company a second 180-day extension, through Dec. 1, to regain compliance with the exchange's minimum $1-per-share bid price requirement for continued listing.

The company was initially notified in December that it was not in compliance with Nasdaq's listing rules and had until June 2 to meet the requirement. As it did not regain compliance during that initial period, Nasdaq has now determined that BloomZ ( BLMZ ) is eligible for an additional extension.

BloomZ ( BLMZ ) said it will continue to monitor its bid price and will consider all available options to regain compliance.

The company's shares were up nearly 7% in after-hours trading.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-BioNTech To Acquire Biotheus To Boost Oncology Strategy
BRIEF-BioNTech To Acquire Biotheus To Boost Oncology Strategy
Nov 13, 2024
Nov 13 (Reuters) - BioNTech SE: * BIONTECH TO ACQUIRE BIOTHEUS TO BOOST ONCOLOGY STRATEGY * BIONTECH SE - DEAL VALUED AT $800 MILLION PLUS $150 MILLION IN MILESTONE PAYMENTS * BIONTECH SE - TO GAIN FULL GLOBAL RIGHTS TO BNT327/PM8002 Source text: Further company coverage: ...
Griffon's Fiscal Q4 Adjusted Earnings, Revenue Rise; Provides Fiscal 2025 Revenue Guidance
Griffon's Fiscal Q4 Adjusted Earnings, Revenue Rise; Provides Fiscal 2025 Revenue Guidance
Nov 13, 2024
08:13 AM EST, 11/13/2024 (MT Newswires) -- Griffon (GFF) reported fiscal Q4 adjusted earnings Wednesday of $1.47 per diluted share, up from $1.19 a year earlier. Analysts polled by Capital IQ expected $1.18. Revenue for the quarter ended Sept. 30 was $659.7 million, compared with $641.4 million a year earlier. Analysts surveyed by Capital IQ expected $641.2 million. The company...
BRIEF-Entero Therapeutics Announces Proposed Reverse Merger With Journey Therapeutics
BRIEF-Entero Therapeutics Announces Proposed Reverse Merger With Journey Therapeutics
Nov 13, 2024
Nov 13 (Reuters) - Entero Therapeutics Inc ( ENTO ): * ENTERO THERAPEUTICS ANNOUNCES PROPOSED REVERSE MERGER WITH JOURNEY THERAPEUTICS, A CLINICAL STAGE, FIRST-IN-CLASS, NEXT-GENERATION ADC-RIVALLING NANO-IMMUNOCONJUGATES BIOPHARMACEUTICAL COMPANY * ENTERO THERAPEUTICS INC ( ENTO ) - JOURNEY SHAREHOLDERS TO ACQUIRE 99% OF ENTERO EQUITY * ENTERO THERAPEUTICS INC ( ENTO ) - COMBINED COMPANY TO OPERATE AS JOURNEY THERAPEUTICS...
BRIEF-Coterra Announces Accretive Permian Basin Acquisitions
BRIEF-Coterra Announces Accretive Permian Basin Acquisitions
Nov 13, 2024
Nov 13 (Reuters) - Coterra Energy Inc ( CTRA ): * COTERRA ANNOUNCES ACCRETIVE PERMIAN BASIN ACQUISITIONS * COTERRA ENERGY INC ( CTRA ): PROPOSED DEAL FOR AGGREGATE CONSIDERATION OF $3.95 BILLION * COTERRA ENERGY INC ( CTRA ): CONSIDERATION CONSISTING OF $2.95 BILLION OF CASH AND $1.0 BILLION OF COTERRA COMMON STOCK * COTERRA: CASH PORTION OF DEAL EXPECTED...
Copyright 2023-2026 - www.financetom.com All Rights Reserved